Compare RACE & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RACE | TAK |
|---|---|---|
| Founded | 1947 | 1781 |
| Country | Italy | Japan |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.7B | 59.8B |
| IPO Year | 2015 | 2007 |
| Metric | RACE | TAK |
|---|---|---|
| Price | $397.13 | $20.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $453.30 | $22.77 |
| AVG Volume (30 Days) | 359.5K | ★ 2.5M |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | 1.07% | ★ 2.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.89 | $4.40 |
| Revenue Next Year | $8.22 | $1.95 |
| P/E Ratio | ★ $34.59 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $312.51 | $12.99 |
| 52 Week High | $437.15 | $20.13 |
| Indicator | RACE | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 50.52 | 72.61 |
| Support Level | $381.67 | $17.58 |
| Resistance Level | $417.16 | N/A |
| Average True Range (ATR) | 5.43 | 0.28 |
| MACD | 1.49 | 0.17 |
| Stochastic Oscillator | 74.28 | 98.11 |
Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2025, the company sold 13,640 vehicles at an average price over EUR 520,000, with more than 80% of its vehicles being sold to existing Ferrari clients. Eighty-four percent of revenue is generated from the sale of cars and spare parts, and 10% from sponsorship, commercial, and brand activities, including racing and lifestyle activities. In 2025, the Europe, Middle East, and Africa region accounted for 49%, the Americas for 32%, mainland China, Hong Kong, and Taiwan for 7%, and the rest of Asia for 12%.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.